Amplion Research

Amplion Research operates as a data intelligence company, providing a specialized platform for the life sciences sector. Founded in 2013 by biotech veterans John Audette and Adam Carroll, the Bend, Oregon-based firm was established to address the growing need for precision medicine intelligence. Carroll, who served as Chief Scientific Officer, brought extensive experience in biomedical and data science, including a Ph.D. in Biochemistry and Molecular Biology from UCSF and a background leading technology development at Bend Research.

The company's core business revolves around its AI-powered intelligence platform, which equips life science commercial teams with actionable insights for strategic decision-making. It serves pharmaceutical and diagnostic developers by helping them identify and prioritize business opportunities to accelerate sales and marketing efforts. The platform functions by analyzing vast amounts of unstructured data from over 35 million sources, including scientific publications, clinical trials, news articles, and regulatory databases. Using proprietary machine learning and natural language processing algorithms, it turns this raw information into contextualized, accessible insights. This enables clients to pinpoint ideal customers, track key accounts, and monitor events in real-time, integrating directly with CRM systems to streamline sales workflows.

One of Amplion's key products was BiomarkerBase™, a knowledge base and analytics platform focused on clinical biomarkers. This tool provided evidence-based information to support strategic decisions in drug and diagnostic development by surfacing relationships between biomarkers, diseases, and drugs. The platform was designed to give users a comprehensive view of the clinical biomarker landscape, including those in laboratory-developed tests (LDTs) and FDA-approved tests. In August 2019, Amplion secured an undisclosed amount in a Series A funding round led by Greycroft, with participation from Revolution's Rise of the Rest Seed Fund and Imagen Capital Partners, to expand its operations and product development. A significant milestone occurred in September 2022, when Science and Medicine Group (SMG) acquired the assets of Amplion. This acquisition integrated Amplion's knowledge base and data architecture into SMG's portfolio, aiming to enhance the delivery of comprehensive insights to commercial life science organizations. Following the acquisition, Amplion's CEO Chris Capdevila remained as a consultant, and its employees joined SMG.

Keywords: life sciences, data intelligence, precision medicine, biomarker analysis, pharmaceutical developers, diagnostic development, lead generation, market intelligence, machine learning, AI platform, commercial teams, drug discovery, clinical trials data, sales enablement, biotech, healthcare data, business intelligence, opportunity sourcing